Phase 2 study of Renzapride in patients with diabetic gastroparesis
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Renzapride (Primary)
- Indications Diabetic gastroparesis
- Focus Registrational; Therapeutic Use
- Sponsors EndoLogic
- 09 Aug 2017 According to an EndoLogic media release, company anticipate submitting the IND in the fourth quarter of 2017, with dosing of the first patient expected in the second quarter of 2018.
- 09 Aug 2017 According to an EndoLogic media release, if successful, this study will be considered as one of two pivotal trials essential to submit an NDA.
- 03 May 2017 According to an EndoLogic media release, the FDA has scheduled a pre-IND meeting with EndoLogic to discuss the requirements for this proposed phase II study. The meeting will be on July 25, 2017.